PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836311
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1836311
Transcatheter Embolization and Occlusion Devices Market size was valued at US$ 5,493.20 Million in 2024, expanding at a CAGR of 7.80% from 2025 to 2032.
Transcatheter embolization and occlusion devices enable the insertion or passage of a synthetic embolus into the body via a specific body part while utilizing a catheter. Transcatheter embolization is a minimally invasive technique used in interventional radiology to stop blood flow to cancerous tumors. To identify many strategies for targeting tumors, synthetic materials are occasionally used to coat chemotherapeutic medications in order to perform simultaneous acts of blood supply blocking and cytotoxicity.
Transcatheter Embolization and Occlusion Devices Market- Market Dynamics
Increasing demand for minimally invasive techniques fuels market growth.
The growing demand for minimally invasive techniques is expected to drive the growth of the transcatheter embolization and occlusion device market in the near future. Minimally invasive surgeries use small incisions or natural body openings to access and treat internal structures, organs, or tissues, reducing trauma to the patient's body. Transcatheter embolization and occlusion devices play an important role in these techniques, providing numerous benefits such as reduced invasiveness, shorter recovery times, targeted treatment, less pain, lower complication risks, and the possibility of outpatient procedures. For instance, Intuitive Surgical Inc., a US-based technology corporation specializing in minimally invasive medical products, reported that approximately 1,875,000 surgical procedures were performed using da Vinci surgical systems in 2022, up 18% from about 1,594,000 in 2021. As a result, the growing demand for minimally invasive techniques is a major driver in the transcatheter embolization and occlusion devices market.
Transcatheter Embolization and Occlusion Devices Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.80% over the forecast period (2025-2032)
Based on Product segmentation, non-coil was predicted to show maximum market share in the year 2024
On the basis of region, North American was the leading revenue generator in 2024
The Global Transcatheter Embolisation and Occlusion Devices Market is segmented on the basis of Product and Region.
Two product-based categories comprise the market: Coil and Non-Coil. The non-coil segment will dominate the market with the highest revenue share in 2025, owing to its versatility and effectiveness in a variety of clinical applications. Non-coil devices, such as liquid embolic agents and particle embolization products, provide precise and controlled embolization, which is ideal for treating complex vascular conditions. Their ability to navigate difficult anatomy and provide superior results with minimal complications has earned them high praise among interventional radiologists and surgeons. This growing preference has contributed to the segment's market dominance.
Transcatheter Embolization and Occlusion Devices Market- Geographical Insights
The North American transcatheter embolization and occlusion device market will dominate the global market in 2025. This is due to the increased use of interventional radiology (IR) procedures. Uterine Fibroid Embolization (UFE), a minimally invasive IR procedure, is increasingly popular as a treatment option for symptomatic uterine fibroids. This nonsurgical approach allows for faster recovery and reduces the need for hysterectomy. Rising patient demand for less invasive treatments, combined with increased awareness among healthcare providers, is driving up the use of embolization devices and expanding the market for these innovative solutions. These devices are used to treat atrial fibrillation and varicose veins.
The Asia Pacific transcatheter embolization and occlusion device market is expected to grow the fastest between 2025 and 2032. The growing prevalence of cancer in the region is driving up demand for these devices. They provide effective treatment options for a variety of cancers, including liver and lung cancer, where embolization is an important part of tumor management. Rising healthcare investments are fueling market growth by increasing access to advanced medical technologies and improving healthcare infrastructure. This combination of rising cancer rates and expanding healthcare capabilities is expected to propel the transcatheter embolization and occlusion devices industry forward across the region.
The Transcatheter Embolization and Occlusion Devices Market is highly competitive, with Abbott, Boston Scientific Corporation, Terumo Corporation, Medtronic, and DePuy Synthes (Johnson & Johnson) leading the way. These companies provide a diverse range of innovative devices, such as embolization coils, vascular plugs, and liquid embolic agents, which are frequently integrated with advanced imaging and catheter navigation systems. The competition revolves around technological innovation, miniaturization, and increased safety and efficacy for oncology, neurology, and peripheral vascular procedures.
In January 2025, Stryker has agreed to acquire Inari Medical for USD 4.9 billion, expanding its presence in venous thromboembolism care.
In July 2025, Teleflex acquired BIOTRONIK's vascular intervention business for EUR 760 million, expanding its portfolio to include drug-coated balloons and the Freesolve resorbable scaffold.